Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab

Moses, Jonathan; Alkhouri, Naim; Shannon, Angela; Feldstein, Ariel E.; Carter–Kent, Christine

doi:10.1002/ibd.21892

Cited by 13 publications

(14 citation statements)

References 4 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No increase in disease activity. Moses et al [ 54 ] 12 pIBD 12 anti-TNFα 2 MTX 3 Seroconversion rate was 92 %. – Hepatitis B virus (DNA) Kasapçopur et al [ 26 ] 39 JIA 41 HC 20 GC 22 MTX 2B Seroprotection in 38/39 patients vaccination, comparable to HC.…”

Section: Vaccine Immunogenicity In Paediatric Patients With Rheumaticmentioning

confidence: 99%

“…One new study on the immunogenicity of the hepatitis A virus (HAV) vaccine was found [ 54 ]. Two studies including 57 patients showed an adequate immunogenicity in patients not using anti-TNFα treatment [ 40 , 53 ].…”

Section: Vaccine Immunogenicity In Paediatric Patients With Rheumaticmentioning

confidence: 99%

“…Two studies including 57 patients showed an adequate immunogenicity in patients not using anti-TNFα treatment [ 40 , 53 ]. One study in twelve children with inflammatory bowel syndrome using anti-TNFα treatment showed an adequate seroconversion rate of 92 % [ 54 ] (Table 2 ).…”

Section: Vaccine Immunogenicity In Paediatric Patients With Rheumaticmentioning

confidence: 99%

“…RCTs, in which patients with rheumatic diseases are vaccinated with adjuvanted versus unadjuvanted vaccines are lacking. In this review, we found 12 reports including 614 patients that studied an adjuvanted non-live vaccine [ 15 , 16 , 21 , 26 , 30 , 35 , 39 , 41 , 52 – 54 , 59 ]. Seven reports including 499 patients studied a non-adjuvanted non-live vaccine [ 24 , 25 , 31 , 32 , 36 , 56 , 58 ].…”

Section: Adjuvant Safety In Paediatric Patients With Rheumatic Diseasmentioning

confidence: 99%

See 3 more Smart Citations

Vaccinations in Paediatric Rheumatology: an Update on Current Developments

2015

View full text Add to dashboard Cite

In 2011, the European League Against Rheumatism (EULAR) published recommendations regarding the vaccination of children with rheumatic diseases. These recommendations were based on a systematic literature review published in that same year. Since then, the evidence body on this topic has grown substantially. This review provides an update of the systematic literature study of 2011, summarizing all the available evidence on the safety and immunogenicity of vaccination in paediatric patients with rheumatic diseases. The current search yielded 21 articles, in addition to the 27 articles described in the 2011 review. In general, vaccines are immunogenic and safe in this patient population. The effect of immunosuppressive drugs on the immunogenicity of vaccines was not detrimental for glucocorticosteroids and methotrexate. Biologicals could accelerate a waning of antibody levels over time, although most patients were initially protected adequately. Overall, persistence of immunological memory may be reduced in children with rheumatic diseases, which shows the need for (booster) vaccination. This update of the 2011 systematic literature review strengthens the evidence base for the EULAR recommendations, and it must be concluded that vaccinations in patients with rheumatic diseases should be advocated.

show abstract

Section: Vaccine Immunogenicity In Paediatric Patients With Rheumaticmentioning

confidence: 99%

Section: Vaccine Immunogenicity In Paediatric Patients With Rheumaticmentioning

confidence: 99%

Section: Vaccine Immunogenicity In Paediatric Patients With Rheumaticmentioning

confidence: 99%

Section: Adjuvant Safety In Paediatric Patients With Rheumatic Diseasmentioning

confidence: 99%

See 2 more Smart Citations

Vaccinations in Paediatric Rheumatology: an Update on Current Developments

2015

View full text Add to dashboard Cite

show abstract

“…The efficacy and safety of primary vaccinations in pediatric IBD patients has been investigated in a limited number of studies (Table 3 ). The Hepatitis A vaccine series is highly immunogenic in pediatric IBD patients with seroconversion rates over 90% and has no significant differences in response between case patients compared to healthy controls; the vaccine was also well tolerated[ 25 - 27 ]. The HepB series does not have the same immunogenicity as Hepatitis A (Table 3 ).…”

Section: Resultsmentioning

confidence: 99%

Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease

Nguyen¹,

Minar²,

Jackson³

et al. 2017

WJG

View full text Add to dashboard Cite

AIMTo determine the vaccination rates in pediatric immunosuppression-dependent inflammatory bowel disease (IBD) and review the safety and efficacy of vaccinations in this population.METHODSThe electronic medical records from October 2009 to December 2015 of patients diagnosed with IBD at 10 years of age or younger and prescribed anti-tumor necrosis factor alpha (anti-TNF-α) therapy were reviewed for clinical history, medication history, vaccination history, and hepatitis B and varicella titers. Literature discussing vaccination response in IBD patients were identified through search of the MEDLINE database and reviewed using the key words “inflammatory bowel disease”, “immunization”, “vaccination”, “pneumococcal”, “varicella”, and “hepatitis B”. Non-human and non-English language studies were excluded. Search results were reviewed by authors to select articles that addressed safety and efficacy of immunizations in inflammatory bowel disease.RESULTSA total of 51 patients diagnosed with IBD prior to the age of 10 and receiving anti-TNF-α therapy were identified. Thirty-three percent of patients (17/51) had incomplete or no documentation of vaccinations. Sixteen case reports, cohort studies, cross-sectional studies, and randomized trials were determined through review of the literature to describe the safety and efficacy of hepatitis B, pneumococcal, and varicella immunizations in adult and pediatric patients with IBD. These studies showed that patients safely tolerated the vaccines without significant adverse effects. Importantly, IBD patients receiving immunosuppressive medications, particularly anti-TNF-α treatment, have decreased vaccine response compared to controls. However, the majority of patients are still able to achieve protective levels of specific antibodies.CONCLUSIONImmunizations have been shown to be well-tolerated and protective immunity can be achieved in patients with IBD requiring immunosuppressive therapy.

show abstract

Vaccination with Non-live Vaccines

Blanchard-Rohner

Pittet

2022

In Clinical Practice

View full text Add to dashboard Cite

Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab

Cited by 13 publications

References 4 publications

Vaccinations in Paediatric Rheumatology: an Update on Current Developments

Vaccinations in Paediatric Rheumatology: an Update on Current Developments

Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease

Vaccination with Non-live Vaccines

Contact Info

Product

Resources

About